ABSTRACT
Objective Coronavirus disease 2019 (Covid 19) started in China in December 2019 and spread all over the world, is more progressive in patients who are elderly and with chronic diseases. Especially kidney involvement affects the survival of patients. In this study, we analyzed Covid 19 patients who developed acute kidney injury treated in our unit, retrospectively.
Matherials The clinical and laboratory data of 610 patients who hospitalized due to Covid 19 pandemic between 01.06.2020 and 30.06.2021 in the intensive care and other clinics of our hospital evaluated from the records, retrospectively. One hundred-fourty patients diagnosed with AKI according to the criteria of KDIGO (Kidney Disease Global Outcomes). The patients divided into two groups as KDIGO stage 1 and 2, 3.
Results The median age in both groups was 70 (35-92) and 73 (35-90) years. Approximately seventy percent of them were over 65 years old. Almost all of the patients had hypertension. Most of the patients were using angiotensin converting enzyme inhibitors (ACE inh) or angiotensin receptor blockers (ARB) (84%). AKI was present at the time of admission (61.9%) in the KDIGO 1 group and at the time of hospitalization (64.3%) in the KDIGO 2, 3 group. The mortality rate was higher in stage 2-3 AKI patients (35.7%). Ferritin and fibrinogen levels were high in the KDIGO 2, 3 group, while lymphocyte levels were low.
Conclusion AKI can be seen at the time of admission and during treatment in patients who are hospitalized and treated due to Covid 19. Covid 19 is more mortal in patients with advanced AKI.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Bursa City Hospital gave ethical approval for this work (08.07.2020-2020/9)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Olgun DENIZ, University of Health Sciences, Bursa Faculty of Medicine, Department of Geriatrics, Dogankoy mevki, Nilufer/BURSA., Tel No: +90 535 6889477, Email: olgundeniz2001{at}yahoo.com
Baris DONER, University of Health Sciences, Bursa Faculty of Medicine, Department of Nephrology, Dogankoy mevki, Nilufer/BURSA., Tel No: +90 533 2661232, Email: drbarisdoner{at}yahoo.com
Isa KILIC, University of Health Sciences, Bursa Faculty of Medicine, Department of Intensive Care, Anesthesia and Reanimation, Dogankoy mevki, Nilufer/BURSA., Tel No: +90 505 3513835, Email: kilicisaicu{at}gmail.com
Canan DEMIR, University of Health Sciences, Bursa Faculty of Medicine, Department of Clinical Microbiology and Infection Diseases, Dogankoy mevki, Nilufer/BURSA., Tel No: +90 541 9525447, Email: drcanandemir{at}hotmail.com
Abdulkadir SAHIN, University of Health Sciences, Bursa Faculty of Medicine, Department of Internal Medicine, Dogankoy mevki, Nilufer/BURSA., Tel No: +90 506 3305643, Email: draksca{at}gmail.com
Data Availability
All data produced in the present study are available upon reasonable request to the authors